3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
11
Phase 1
4
Phase 3
2
Phase EARLY_PHASE1
1
Status
Active not recruiting
2
Recruiting
1
Not yet recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Conditions
Stomach Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Adenocarcinoma Of Esophagus
1
Interventions
Carboplatin
108
Cisplatin
98
Paclitaxel
79
pembrolizumab
70
Gemcitabine
60
Pemetrexed
49
Cyclophosphamide
48
Dexamethasone
47
Docetaxel
46
durvalumab
44
Capecitabine
44
Radiotherapy
42
Doxorubicin
40
Lenalidomide
38
Specimen Handling
37
Nivolumab
37
Oxaliplatin
35
Rituximab
34
Magnetic Resonance Spectroscopy
33
Fluorouracil
33
Etoposide
32
Bevacizumab
32
Vincristine
30
atezolizumab
29
Radiation
28
Leucovorin
28
Bortezomib
26
Prednisone
23
Letrozole
23
Fulvestrant
23
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Active not recruiting
×
zimberelimab
×
Clear all
NCT05568095
2026-05-08
STAR-221
Arcus Biosciences, Inc.
Phase 3
Active not recruiting
1,040 enrolled
NCT05502237
2026-01-30
STAR-121
Gilead Sciences
Phase 3
Active not recruiting
1,021 enrolled